[{"Assets_0_Q2_USD":449889000.0,"CommonStockSharesOutstanding_0_Q2_shares":30094631.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-5112000.0,"NetIncomeLoss_1_Q2_USD":-10620000.0,"NetIncomeLoss_2_Q2_USD":-28333000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":30028985.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":29933164.0,"StockholdersEquity_0_Q2_USD":245589000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":96080000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":183715000.0,"Ticker":"NVRO","CIK":"1444380","name":"NEVRO CORP","OfficialName":"Nevro Corp. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"2648227724.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Electromedical & Electrotherapeutic Apparatus","Market":"NYSE","SP500":"nan","filed":"20180802"}]